Valsartan-induced improvement in insulin sensitivity is not paralleled by changes in microvascular function in individuals with impaired glucose metabolism

Journal of Hypertension

Volumn 29, Issue 10, 2011, Pages 1955-1962

  Van Der Zijl, Nynke J ^a   Serné, Erik H ^a   Goossens, Gijs H ^b   Moors, Chantalle C M ^b   Ijzerman, Richard G ^a   Blaak, Ellen E ^b   Diamant, Michaela ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Angiotensin receptor blocker; Impaired fasting glucose; Impaired glucose tolerance; Insulin sensitivity; Microvascular function

Indexed keywords

ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN; ADIPOCYTOKINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; AUTACOID; CYTOKINE; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ADULT; AGE DISTRIBUTION; ARTERY OCCLUSION; ARTICLE; BODY MASS; CAPILLAROSCOPY; CAPILLARY DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MICROCIRCULATION; MICROVASCULARIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION; BLOOD; CAPILLARY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM; MICROVASCULATURE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADIPOKINES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD GLUCOSE; CAPILLARIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; MICROVESSELS; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 84855991759     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834a7667     Document Type: Article

References (40)

1. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-759. (Pubitemid 46354366)
2. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007;334:299.
3. Lastra-Lastra G, Sowers JR, Restrepo-Erazo K, Manrique-Acevedo C, Lastra-Gonzalez G. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin Endocrinol (Oxf) 2009;71:1-6.
4. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of newonset diabetes. J Hypertens 2005;23:463-473. (Pubitemid 40684700)
5. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, et al. Effects of valsartan comparedtoamlodipine on preventing type 2diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006;24:1405-1412. (Pubitemid 43948341)
6. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-1490.
7. Fogari R, Preti P, Zoppi A, Mugellini A, Corradi L, Lazzari P, et al. Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. Intern Med 2008;47:1851-1857.
8. Nishimura H, Sanaka T, Tanihata Y, Naito T, Higuchi C, Otsuka K. Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens Res 2008;31:1611-1618.
9. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-873. (Pubitemid 19238619)
10. Goossens GH, Blaak EE, Saris WH, van Baak MA. Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J Clin Endocrinol Metab 2004;89:2690-2696. (Pubitemid 38766351)
11. Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 2009;52:752-764.
12. Serne EH, Stehouwer CD, ter Maaten JC, ter Wee PM, Rauwerda JA, Donker AJ, et al. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation 1999;99:896-902. (Pubitemid 29094303)
13. Serne EH, de Jongh RT, Eringa EC, IJzerman RG, Stehouwer CD. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 2007;50:204-211. (Pubitemid 46986042)
14. Serne EH, Gans RO, ter Maaten JC, ter Wee PM, Donker AJ, Stehouwer CD. Capillary recruitment is impaired in essential hypertension and relates to insulin's metabolic and vascular actions. Cardiovasc Res 2001;49:161-168.
15. Kraemer-Aguiar LG, Maranhao PA, Sicuro FL, Bouskela E. Microvascular dysfunction: a direct link among BMI, waist circumference and glucose homeostasis in young overweight/obese normoglycemic women? Int J Obes (Lond) 2010;34:111-117.
16. de Jongh RT, Serne EH, IJzerman RG, de Vries G, Stehouwer CD. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 2004;109:2529-2535. (Pubitemid 38720552)
17. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999;48:1856-1862. (Pubitemid 29415208)
18. Prior JO, Quinones MJ, Hernandez-Pampaloni M, Facta AD, Schindler TH, Sayre JW, et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 2005;111:2291-2298. (Pubitemid 40647063)
19. de Jongh RT, IJzerman RG, Serne EH, Voordouw JJ, Yudkin JS, de Waal HA, et al. Visceral and truncal subcutaneous adipose tissue are associated with impaired capillary recruitment in healthy individuals. J Clin Endocrinol Metab 2006;91:5100-5106. (Pubitemid 44917357)
20. de Cavanagh EM, Ferder LF, Ferder MD, Stella IY, Toblli JE, Inserra F. Vascular structure and oxidative stress in salt-loaded spontaneously hypertensive rats: effects of losartan and atenolol. Am J Hypertens 2010;23:1318-1325.
21. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223. (Pubitemid 9249478)
22. Pries AR, Secomb TW, Gaehtgens P. Structural autoregulation of terminal vascular beds: vascular adaptation and development of hypertension. Hypertension 1999;33:153-161. (Pubitemid 29061856)
23. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment? Circulation 2001;104:735-740. (Pubitemid 32738532)
24. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci U S A 1996;93:12490-12495. (Pubitemid 26367171)
25. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76-81. (Pubitemid 36842239)
26. Chai W, Wang W, Liu J, Barrett EJ, Carey RM, Cao W, et al. Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. Hypertension 2010;55:523-530.
27. Rizzoni D, Pasini E, Flati V, Rodella LF, Paiardi S, Assanelli D, et al. Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats. J Hypertens 2008;26:1595-1601.
28. Sabino B, Lessa MA, Nascimento AR, Rodrigues CA, Henriques MG, Garzoni LR, et al. Effects of antihypertensive drugs on capillary rarefaction in spontaneously hypertensive rats: intravital microscopy and histologic analysis. J Cardiovasc Pharmacol 2008;51:402-409. (Pubitemid 351572240)
29. Debbabi H, Bonnin P, Levy BI. Effects of blood pressure control with perindopril/indapamide on the microcirculation in hypertensive patients. Am J Hypertens 2010;23:1136-1143.
30. Levy BI, Schiffrin EL, Mourad JJ, Agostini D, Vicaut E, Safar ME, et al. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation 2008;118:968-976.
31. Jonk AM, Houben AJ, de Jongh RT, Serne EH, Schaper NC, Stehouwer CD. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology (Bethesda) 2007;22:252-260.
32. Serne EH, IJzerman RG, Gans RO, Nijveldt R, de Vries G, Evertz R, et al. Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia. Diabetes 2002;51:1515-1522. (Pubitemid 34826619)
33. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801. (Pubitemid 44033299)
34. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 2007;112:375-384. (Pubitemid 46587452)
35. Zhou MS, Schulman IH, Raij L. Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension. Am J Physiol Heart Circ Physiol 2009;296:H833-H839.
36. Kramer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002;90:770-776. (Pubitemid 34633892)
37. Tomiyama H, Motobe K, Zaydun G, Koji Y, Yambe M, Arai T, et al. Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan. Am J Hypertens 2005;18(2 Pt 1):178-182. (Pubitemid 40332546)
38. Holowatz LA, Thompson-Torgerson CS, Kenney WL. The human cutaneous circulation as a model of generalized microvascular function. J Appl Physiol 2008;105:370-372.
39. Lee MH, Song HK, Ko GJ, Kang YS, Han SY, Han KH, et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int 2008;74:890-900.
40. Henriksen EJ. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007;293:R974-R980. (Pubitemid 47358914)